Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, the company's holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”) received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and Jinsai Pharmaceutical's application for registration of drugs produced domestically produced in GenSci161 injection was approved. GenScI 161 injection is a therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It has now been approved to conduct clinical trials for connective tissue disease-related interstitial lung disease (CTD-ILD) indications.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.